NEW DELHI and DUBAI, UAE, Jan. 10, 2025 /PRNewswire/ — Gryffin Capitalist, a global leader in corporate services, is proud to announce its expansion, which now allows entrepreneurs, investors, and businesses to set up companies in over 30 offshore locations across the globe. Emphasizing company incorporation with ease, banking assistance, and e-commerce solutions, Gryffin Capitalist continues to simplify global business expansion.

Since its inception in 2017, Gryffin Capitalist has helped approximately 1,000 clients representing more than 50 countries launch their entrepreneurial spirit. Pre and post-incorporation services assist the company in setting up businesses at any scale. Due to its excellence and efficient business design processes, Gryffin Capitalist ensures that it will be one of the companies that succeed in the fierce global markets, making it an ideal partner for offshore company formation.

Unparalleled Expertise in Offshore Locations

Gryffin Capitalist specializes in incorporating businesses in sought-after offshore jurisdictions, such as the British Virgin Islands (BVI), Seychelles, Belize, Malta, and St. Vincent and the Grenadines. These destinations are famous for their tax benefits, legal stability, and privacy protections, making them ideal for global entrepreneurs.

British Virgin Islands (BVI): Gryffin Capitalist offers tailored company registration in BVI, starting at $1,450. With options for banking assistance and executive packages, clients enjoy fast, efficient registration within 2–3 days.Seychelles: Entrepreneurs can opt for Seychelles company registration packages starting at $770. Seychelles International Business Companies (IBCs) offer tax efficiency, asset protection, and privacy. Gryffin Capitalist ensures incorporation is completed quickly and effortlessly.Belize: Known for 0% taxes and no exchange controls, Gryffin Capitalist simplifies Belize company registration with packages starting at $1,350, providing comprehensive support, including bank account setup.St. Vincent and the Grenadines: This jurisdiction is ideal for financial sector businesses like forex and crypto. Gryffin Capitalist’s St. Vincent and the Grenadines company formation packages include banking support, tax exemptions, and tailored incorporation services starting at $1,200.

Driving Global Innovation for SMEs and Entrepreneurs

Gryffin Capitalist’s services are tailored for entrepreneurs, SMEs, and professional intermediaries, enabling them to compete effectively in global markets. The company’s innovative solutions include virtual offices, accounting, auditing, and legal compliance services, ensuring businesses operate efficiently while adhering to local laws and industry standards.

“Since 2017, our mission has been to empower entrepreneurs and businesses worldwide. By expanding to over 30 offshore locations, we are making global business incorporation more accessible than ever,” said Ankit Singh, Business Development Executive, Gryffin Capitalist.

Client-Centric Excellence and Vision

The company’s commitment to quality is reflected in its 100% customer satisfaction rate and personalized services. With over 25 team members working collaboratively, Gryffin Capitalist prioritizes continuous improvement and innovation, leveraging client feedback to enhance service delivery. “Our vision is to help every entrepreneur achieve their business dreams, by simplifying the incorporation process and unlocking global opportunities,” Ankit added.

About Gryffin Capitalist

Gryffin Capitalist is a leading provider of corporate services, offering company incorporation, banking assistance, e-commerce solutions, and more. The company specializes in delivering tailored solutions designed to help businesses navigate global markets, adapt to changing customer needs, and seize new growth opportunities.

View original content:https://www.prnewswire.com/in/news-releases/gryffin-capitalist-expands-global-reach-assisting-entrepreneurs-to-incorporate-in-over-30-offshore-locations-302347914.html

MINNEAPOLIS, Jan. 10, 2025 /PRNewswire/ — Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of new designer proteins engineered using advanced Artificial Intelligence (AI) based design platforms and protein evolutionary workflows. This expanded portfolio from Bio-Techne’s R&D Systems brand includes IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable (available both for research use only (RUO) and made under good manufacturing processes (GMP) for therapeutic development), as well as Wnt/RSPO1 Agonist, Wnt/RSPO2 Agonist, and Wnt/RSPO3 Agonist proteins.

These innovative recombinant proteins are designed and engineered to address critical needs in cellular therapy workflows and research applications, including improved cell culture performance and optimized cell expansion. Leveraging generative AI trained on data developed over almost five decades of proteomic leadership, protein library evolution, and rational design, Bio-Techne’s expanded portfolio delivers next-generation cytokines and growth factors with tailored functionalities such as hyperactivity, enhanced receptor affinities, and improved heat stability.

“Our growing portfolio of designer proteins combine cutting-edge AI technology and innovative protein engineering,” said Will Geist, President, Protein Sciences Segment. “This expanded portfolio empowers our customers with versatile, high-performance solutions to boost the production of immune cells and enhance regenerative medicine cell therapies. Bio-Techne remains committed to developing the tools and workflow solutions our customers need to advance innovative cell therapies in both clinical and research settings.”

The new products include:

IL-2 Heat Stable Agonist: Engineered with enhanced thermal stability and altered receptor affinity for improved biological activity, ideal for cellular therapy applications such as CAR T-cell or Tumor-infiltrating lymphocytes (TIL) expansion.

Activin A Hyperactive: Optimized for superior performance in regenerative medicine cell differentiation applications.

FGF basic Heat Stable: A robust and versatile growth factor designed for improved protein stability and performance for stem cell culture applications, available in both RUO and GMP formats to support cell therapy manufacturing and advanced research.

Wnt/RSPO1, Wnt/RSPO2, and Wnt/RSPO3 Agonists: Key reagents for advancing stem cell research, organoid development, and regenerative medicine.

With this expanded portfolio, Bio-Techne continues to lead the way in delivering disruptive innovations to the life sciences and therapeutic development communities. Bio-Techne designer proteins are available as part of our market leading R&D Systems branded portfolio of proteins. For more information about these AI Modified Proteins, visit our website.

About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has over 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.

Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-expands-rd-systems-ai-engineered-designer-protein-portfolio-to-advance-cell-therapy-and-regenerative-medicine-302347098.html

SOURCE Bio-Techne Corporation

LONDON, Jan. 10, 2025 /PRNewswire/ — LGC has announced that Joydeep Goswami is joining its Board of Directors and Executive Leadership Team (ELT) as President and Chief Executive Officer (CEO). Joydeep succeeds Euan O’Sullivan, who decided to step down from his role in early 2024 after fourteen years of outstanding and dedicated service. Euan has worked closely with the LGC Board since then on the appointment of his successor and will be available in an advisory capacity to Joydeep until March 2025.

David King, Non-Executive Chairman of LGC, said: “On behalf of our Board and ELT, we are delighted to welcome Joydeep to LGC. He brings broad international experience in senior leadership roles in life sciences, focused on business transformation. He brings a strong commitment to LGC’s purpose and values, as well as a track record of driving business performance serving customers, colleagues, and shareholders.”

David added: “On behalf of our Board, ELT and colleagues, we would also like to take this opportunity to thank Euan for his exceptional contribution to LGC. Prior to taking on Group-wide leadership responsibility in the summer of 2020, Euan led the expansion of LGC’s Quality Assurance activities in the 2010s, substantially expanding our Standards business and establishing a leading presence in the clinical diagnostics and food supply chain assurance markets. As President and CEO, he has led LGC with distinction during the COVID-19 pandemic and through the subsequent necessary period of post-pandemic restructuring and renewal, against the backdrop of challenging macro-economic and geopolitical conditions. He leaves us with a tremendous platform to grow from, with the business performing well, a strong leadership team and a transformational investment programme substantially complete. We wish him every success for the future.”

In response to his appointment, Joydeep Goswami said: “LGC is a leading global life sciences tools company that is driven by its purpose – Science for a Safer World. I am pleased to be joining the company at this exciting time, particularly as key strategic capital investment projects reach completion. I look forward to being part of a customer centric company which plays a key role in driving science and innovation forward, partnering with customers to help diagnose, treat, feed and protect the growing global population.”

With over twenty-five years of global experience, Joydeep has a deep background in life sciences tools and a strong track record of developing strategy and leading new product development, partnerships, licensing, and mergers and acquisitions. His experiences as a P&L leader and CFO gives him the ability to bring customer, employee and investor perspectives to setting the strategy and allocating resources to drive strong profitable growth. 

Most recently, Joydeep served as Chief Financial Officer and Chief Strategy and Corporate Development Officer at Illumina. Prior to Illumina, Joydeep held a variety of global and business unit leadership roles with Thermo Fisher Scientific over sixteen years, culminating in his leadership of Thermo Fisher’s Clinical Next Generation Sequencing and Oncology Division. Joydeep also serves on the Board of Biolife Solutions.

Joydeep has an M.S., Ph.D. in Chemical Engineering, an MBA from the Massachusetts Institute of Technology and a bachelor’s degree in chemical engineering from the Indian Institute of Technology, Mumbai. 

About LGC

LGC is a global leader in life science tools, dedicated to partnering with customers to deliver solutions that diagnose, treat, feed, and protect our growing population. With over 180 years of scientific heritage, we collaborate with the scientific community to tackle some of the world’s most complex challenges, responding to global health crises, pioneering precision medicine, and enhancing the safety of food, medicines, and the environment.

Operating in 14 countries, LGC’s products and services are integral to industries that safeguard public health, food, water, and medicine. Our solutions help our diverse customer base—from pharmaceutical companies and diagnostic manufacturers to testing laboratories and food producers—maintain the highest standards of quality, safety, and compliance.

Together with our partners, we work toward a safer, healthier, and more sustainable world, advancing the science that protects people and the planet. For further information visit: www.lgcgroup.com

Media contacts:

Edel McCaffrey, Head of Corporate Communications, LGC Group
edel.mccaffrey@lgcgroup.com
+44 7587 315 615

Magda Bartoszewicz, Director, Corporate Communications, LGC Group
magda.barto@lgcgroup.com
+44 7522 141 822|

Andrew Thomas, LGC Group Corporate Communications
andrew.thomas@lgcgroup.com 
+44 7803 585 254

Logo: https://mma.prnewswire.com/media/2595470/LGC_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/lgc-board-appoints-joydeep-goswami-as-president–chief-executive-302347913.html